Modified release doxycycline composition
Doxycycline formulations with a reduced food effect are disclosed. Particularly disclosed are modified release formulations which can be administered once a day and exhibit a reduced food effect. Methods of treating inflammatory conductions such as rosacea or inflammatory symptoms such as the papules and pustules of rosacea or acne vulgaris are also disclosed.
1. A method of treating inflammatory rosacea or an inflammatory symptom of either rosacea or acne vulgaris in a human patient in need thereof comprising administering a modified release oral composition comprising:
i. about 30 mg to about 50 mg of a doxycycline, based on the equivalent weight of doxycycline base,
ii. one or more water soluble and insoluble polymers, and
iii. one or more pharmaceutically acceptable excipients,
wherein the doxycycline is in an amount of about 15-20% w/w, the water soluble and insoluble polymers are in an amount of about 10-18% w/w, and the pharmaceutically acceptable excipients are in an amount of about 1-20% w/w, based on the total weight of the composition, and wherein said composition is free of any immediate release component, and said composition when subjected to a changeover dissolution study, releases no more than 30% by weight in 30 minutes, in 750 ml of pH 1.2 acidic solution, and has at least one of the following release profile in 950 ml of pH 6.0 buffer solution:
a. less than about 30% in 35 minutes;
b. less than about 60% in 45 minutes; and
c. more than 85% in 60 minutes.
2. The method of claim 1 , wherein said composition is administered to a patient in a total daily dose of about 30 mg to about 40 mg of doxycycline, based on the equivalent weight of doxycycline base.
3. The method of claim 2 , wherein said doxycycline is an acid addition salt of doxycycline.
4. The method of claim 3 , wherein said acid addition salt of doxycycline is doxycycline hyclate.
5. The method of claim 4 , wherein said doxycycline hyclate is present in an amount of about 46 mg.
6. The method of claim 1 , wherein said composition upon oral administration in a fasting state exhibits bioequivalence to a commercially available 40 mg doxycycline composition and wherein said bioequivalence is established by:
a. a 90% Confidence Interval for mean AUC (0-t) , which is between 80% and 125%,
b. a 90% Confidence Interval for mean AUC (0-∞) , which is between 80% and 125%, and
c. a 90% Confidence Interval for mean C max , which is between 80% and 125%.
7. The method of claim 1 , wherein said inflammatory symptom of either rosacea or acne vulgaris is papules and pustules of either rosacea or acne vulgaris.
8. A method of treating inflammatory rosacea or an inflammatory symptom of either rosacea or acne vulgaris in a human patient in need thereof comprising administering a modified release oral composition comprising:
i. about 30 mg to about 50 mg of a doxycycline based on the equivalent weight of doxycycline base,
ii. one or more water soluble and insoluble polymers, and
iii. one or more pharmaceutically acceptable excipients,
wherein the doxycycline is in an amount of about 15-20% w/w, the water soluble and insoluble polymers are in an amount of about 10-18% w/w and the pharmaceutically acceptable excipients are in an amount of about 1-20% w/w, based on the total weight of the composition, and wherein said composition is free of any immediate release component, and said composition exhibits a reduced food effect selected from the group consisting of an AUC of less than about 15% and a C max of less than about 40% upon oral administration to a human.
9. The method of claim 8 , wherein said composition is administered to a patient in a total daily dose of about 30 mg to about 40 mg of doxycycline, based on the equivalent weight of doxycycline base.
10. The method of claim 8 , wherein said doxycycline is an acid addition salt of doxycycline.
11. The method of claim 10 , wherein said acid addition salt of doxycycline is doxycycline hyclate.
12. The method of claim 11 , wherein said doxycycline hyclate is present in an amount of about 46 mg.
13. The method of claim 8 , where said composition upon oral administration in a fasting state exhibits bioequivalence to a commercially available 40 mg doxycycline composition and wherein said bioequivalence is established by:
a. a 90% Confidence Interval for mean AUC (0-t) , which is between 80% and 125%,
b. a 90% Confidence Interval for mean AUC (0-∞) , which is between 80% and 125%, and
c. a 90% Confidence Interval for mean C max , which is between 80% and 125%.
14. The method of claim 8 , wherein said inflammatory symptom of either rosacea or acne vulgaris is papules and pustules of either rosacea or acne vulgaris.
15. A method of treating inflammatory rosacea or an inflammatory symptom of either rosacea or acne vulgaris in a human patient in need thereof comprising administering a modified release oral composition comprising:
i. about 46 mg of doxycycline hyclate,
ii. one or more water soluble and insoluble polymers, and
iii. one or more pharmaceutically acceptable excipients,
wherein doxycycline is in an amount of about 15-20% w/w, the water soluble and insoluble polymers are in an amount of about 10-18% w/w and the pharmaceutically acceptable excipients are in an amount of about 1-20% w/w, based on the total weight of the composition, and said composition is free of any immediate release component, and said composition when subjected to a changeover dissolution study, releases no more than 10% by weight in 30 minutes, in 750 ml of pH 1.2 acidic solution; and has at least one of the following release profile in 950 ml of pH 6.0 buffer solution:
a. less than about 30% in 35 minutes;
b. less than about 60% in 45 minutes; and
c. more than 85% in 60 minutes.
16. The method of claim 1 , wherein said composition exhibits no food effect and is established by following parameters:
(a) a 90% Confidence Interval for mean AUC (0-t) of the composition administered under fed state to human subjects is within 80.00% to 125.00% of a AUC (0-t) of the composition administered to human subjects in a fasting state; and
(b) a 90% Confidence Interval for mean AUC (0-inf) of the composition administered under fed state to human subjects is within 80.00% to 125.00% of a AUC (0-inf) of the composition administered to human subjects in a fasting state.
17. The method of claim 1 , wherein the composition releases no more than 20% in 30 minutes, in 750 ml of pH 1.2 acidic solution.
18. The method of claim 1 , wherein the composition releases no more than 10% in 30 minutes in 750 ml of pH 1.2 acidic solution.
19. The method of claim 8 , wherein said composition has dC/dT value of less than about 80% of the dC/dT value provided by the commercially available 40 mg doxycycline composition, measured in a single dose human pharmacokinetic study in a fasting state and in a time period of T 0 min to T 60 mins.
20. The method of claim 8 , wherein said composition provides a C max of about 200 ng/ml to about 900 ng/ml at 90 minutes.
21. The method of claim 8 , wherein said composition which upon oral administration in a fasting state exhibits bioequivalence to a commercially available 40 mg doxycycline composition.
22. The method of claim 21 , wherein the bioequivalence is established by:
a. a 90% Confidence Interval for mean AUC (0-t) , which is between 80% and 125%,
b. a 90% Confidence Interval for mean AUC (0-∞) , which is between 80% and 125%, and
c. a 90% Confidence Interval for mean C max which is between 80% and 125%.
23. The method of claim 8 , wherein the composition is administered once daily to provide the entire dose of doxycycline.
24. The method of claim 8 , wherein the doxycycline is a hydrate and the hydrate is a monohydrate.